Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa

被引:218
作者
Boulle, Andrew [1 ]
Van Cutsem, Gilles [1 ,2 ]
Hilderbrand, Katherine [1 ,2 ]
Cragg, Carol [3 ]
Abrahams, Musaed [2 ]
Mathee, Shaheed [3 ]
Ford, Nathan [1 ,2 ]
Knight, Louise [2 ]
Osler, Meg [1 ]
Myers, Jonny [1 ]
Goemaere, Eric [2 ]
Coetzee, David [1 ]
Maartens, Gary [4 ]
机构
[1] Univ Cape Town, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa
[2] Prov Govt Western Cape, Med Sans Frontiers, Cape Town, South Africa
[3] Prov Govt Western Cape, Dept Hlth, Cape Town, South Africa
[4] Univ Cape Town, Div Clin Pharmacol, Dept Med, ZA-7925 Cape Town, South Africa
关键词
antiretroviral therapy; cohort study; death registries; HIV; loss to follow-up; resource-limited settings; South Africa; TO-CHILD TRANSMISSION; DISTRICT-WIDE PROGRAM; SUB-SAHARAN AFRICA; RAPID SCALE-UP; CD4 CELL COUNT; VIROLOGICAL FAILURE; FOLLOW-UP; INCOME COUNTRIES; VIRAL LOAD; THERAPY;
D O I
10.1097/QAD.0b013e328333bfb7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: We report on outcomes after 7 years of a community-based antiretroviral therapy (ART) programme in Khayelitsha, South Africa, with death registry linkages to correct for mortality under-ascertainment. Design: This is an observational cohort study. Methods: Since inception, patient-level clinical data have been prospectively captured on-site into an electronic patient information system. Patients with available civil identification numbers who were lost to follow-up were matched with the national death registry to ascertain their vital status. Corrected mortality estimates weighted these patients to represent all patients lost to follow-up. CD4 cell count outcomes were reported conditioned on continuous virological suppression. Results: Seven thousand, three hundred and twenty-three treatment-naive adults (68% women) started ART between 2001 and 2007, with annual enrolment increasing from 80 in 2001 to 2087 in 2006. Of 9.8% of patients lost to follow-up for at least 6 months, 32.8% had died. Corrected mortality was 20.9% at 5 years (95% confidence interval 17.9-24.3). Mortality fell over time as patients accessed care earlier (median CD4 cell count at enrolment increased from 43 cells/mu l in 2001 to 131 cells/mu l in 2006). Patients who remained virologically suppressed continued to gain CD4 cells at 5 years (median 22 cells/mu l per 6 months). By 5 years, 14.0% of patients had failed virologically and 12.2% had been switched to second-line therapy. Conclusion: At a time of considerable debate about future global funding of ART programmes in resource-poor settings, this study has demonstrated substantial and durable clinical benefits for those able to access ART throughout this period, in spite of increasing loss to follow-up. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:563 / U1
页数:11
相关论文
共 50 条
  • [41] Towards Developing an Initial Programme Theory: Programme Designers and Managers Assumptions on the Antiretroviral Treatment Adherence Club Programme in Primary Health Care Facilities in the Metropolitan Area of Western Cape Province, South Africa
    Mukumbang, Ferdinand C.
    van Belle, Sara
    Marchal, Bruno
    van Wyk, Brian
    PLOS ONE, 2016, 11 (08):
  • [42] Long-term Outcome of Children Receiving Antiretroviral Treatment in Rural South Africa Substantial Virologic Failure on First-line Treatment
    Barth, Roos E.
    Tempelman, Hugo A.
    Smelt, Elbert
    Wensing, Annemarie M. J.
    Hoepelman, Andy I.
    Geelen, Sibyl P.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (01) : 52 - 56
  • [43] Temporal Trends in Baseline Characteristics and Treatment Outcomes of Children Starting Antiretroviral Treatment: An Analysis in Four Provinces in South Africa, 2004-2009
    Fatti, Geoffrey
    Bock, Peter
    Eley, Brian
    Mothibi, Eula
    Grimwood, Ashraf
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 58 (03) : E60 - E67
  • [44] Effect of antiretroviral treatment on the risk of tuberculosis during South Africa's programme expansion
    Bachmann, Max O.
    Timmerman, Venessa
    Fairall, Lara R.
    AIDS, 2015, 29 (17) : 2261 - 2268
  • [45] Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa
    Cox, Helen
    Ramma, Lebogang
    Wilkinson, Lynne
    Azevedo, Virginia
    Sinanovic, Edina
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2015, 20 (10) : 1337 - 1345
  • [46] Drug resistance in HIV-infected children living in rural South Africa: Implications of an antiretroviral therapy initiated during the first year of life
    Beghin, Jean-Christophe
    Ruelle, Jean
    Goubau, Patrick
    Van der Linden, Dimitri
    JOURNAL OF CLINICAL VIROLOGY, 2020, 129
  • [47] Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa
    Cox, H.
    Hughes, J.
    Daniels, J.
    Azevedo, V.
    McDermid, C.
    Poolman, M.
    Boulle, A.
    Goemaere, E.
    van Cutsem, G.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2014, 18 (04) : 441 - 448
  • [48] Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007
    Cornell, Morna
    Grimsrud, Anna
    Fairall, Lara
    Fox, Matthew P.
    van Cutsem, Gilles
    Giddy, Janet
    Wood, Robin
    Prozesky, Hans
    Mohapi, Lerato
    Graber, Claire
    Egger, Matthias
    Boulle, Andrew
    Myer, Landon
    AIDS, 2010, 24 (14) : 2263 - 2270
  • [49] Antiretroviral Treatment and Sexual Risk Behavior in South Africa
    Kathryn Risher
    Thomas Rehle
    Leickness Simbayi
    Olive Shisana
    David D. Celentano
    AIDS and Behavior, 2016, 20 : 710 - 716
  • [50] Impact of systematic HIV testing on case finding and retention in care at a primary care clinic in South Africa
    Clouse, Kate
    Hanrahan, Colleen F.
    Bassett, Jean
    Fox, Matthew P.
    Sanne, Ian
    Van Rie, Annelies
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2014, 19 (12) : 1411 - 1419